HAMILTON, N.J., Jan. 10, 2011 /PRNewswire/ — MedAvante, Inc.,
the leader in centralized expert evaluation of treatments for
central nervous system (CNS) disorders, announced the appointment
of Christopher Randolph, PhD, ABPP-CN, to the new position of Vice
President, Neurocognition. Dr. Randolph will lead a growing
team of clinical and training experts and experienced, calibrated
clinicians focusing on Alzheimer’s disease (AD), mild cognitive
impairment (MCI) and other neurocognitive disorders.
“MedAvante has made a serious commitment to helping drug
developers in this vital therapeutic category reduce their risk of
failure due to inconclusive trial results,” said Paul M. Gilbert,
Chief Executive Officer of MedAvante. “Chris Randolph is a
highly accomplished, widely recognized expert in Alzheimer’s
disease clinical trials, and he brings with him a wealth of domain
expertise as well as a highly successful study track record.”
“Having Chris Randolph join our senior scientific leadership
team ideally complements MedAvante’s science-driven methodologies
that are bringing about a paradigm shift in the way CNS clinical
trials are conducted,” said Gilbert.
Dr. Randolph is the author of the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS), a brief
neurocognitive battery used widely around the world. He has
consulted on test development for over 20 years, including the
revisions of the Wechsler intelligence and memory scales. His
extensive experience in CNS clinical trials includes work as an
investigator and consultant, as well as creating and supervising
rater training programs for a large number of Phase 2 and Phase 3
multinational studies in AD, schizophrenia, stroke, hepatic
encephalopathy, and traumatic brain injury.
“The landscape of CNS clinical trials has changed substantially
over the last 10-15 years, particularly in Alzheimer’s disease,”
said Dr. Randolph. “Today’s em
‘/>”/>
